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STUDY PROTOCOL Open Access
Vancomycin versus daptomycin for the treatment
of methicillin-resistant Staphylococcus aureus
bacteremia due to isolates with high vancomycin
minimum inhibitory concentrations: study protocol
for a phase IIB randomized controlled trial
Shirin Kalimuddin1, Rachel Phillips2, Mihir Gandhi2,3, Nurun Nisa de Souza2,3, Jenny GH Low1, Sophia Archuleta4,5,
David Lye6 and Thuan Tong Tan1*
Abstract
Background: Vancomycin is the standard first-line treatment for methicillin-resistant Staphylococcus aureus
bacteremia. However, recent consensus guidelines recommend that clinicians consider using alternative agents
such as daptomycin when the vancomycin minimum inhibitory concentration is greater than 1 ug/ml. To date
however, there have been no head-to-head randomized trials comparing the safety and efficacy of daptomycin and
vancomycin in the treatment of such infections. The primary aim of our study is to compare the efficacy of daptomycin
versus vancomycin in the treatment of bloodstream infections due to methicillin-resistant Staphylococcus aureus isolates
with high vancomycin minimum inhibitory concentrations (greater than or equal to 1.5 ug/ml) in terms of reducing
all-cause 60-day mortality.
Methods/Design: The study is designed as a multicenter prospective open label phase IIB pilot randomized
controlled trial. Eligible participants will be inpatients over 21-years-old with a positive blood culture for
methicillin-resistant Staphylococcus aureus with vancomycin minimum inhibitory concentration of greater than
or equal to 1.5ug/ml. Randomization into intervention or active control arms will be performed with a 1:1 allocation
ratio. We aim to recruit 50 participants over a period of two years. Participants randomized to the active control arm will
receive vancomycin dose-while those randomized to the intervention arm will receive daptomycin. Participants
will receive a minimum of 14 days study treatment.
The primary analysis will be conducted on the intention-to-treat principle. The Fisher’s exact test will be used to
compare the 60-day mortality rate from index blood cultures (primary endpoint) between the two treatment
arms, and the exact two-sided 95% confidence interval will be calculated using the Clopper and Pearson
method. Primary analysis will be conducted using a two sided alpha of 0.05.
Discussion: If results from this pilot study suggest that daptomycin shows significant efficacy in the treatment
of bloodstream infections due to methicillin-resistant Staphylococcus aureus isolates with high vancomycin minimum
inhibitory concentrations, we aim to proceed with a larger scale confirmatory study. This would help guide clinicians
and inform practice guidelines on the optimal treatment for such infections.
Trial registration: The trial is listed on clinicaltrials.gov (NCT01975662, date of registration: 29 October 2013).
Keywords: MRSA, Bacteremia, Daptomycin, Vancomycin
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) has
emerged as one of the most common hospital-acquired
pathogens worldwide. In our local setting in Singapore it
is the predominant antibiotic-resistant pathogen, account-
ing for more than one-third of the clinical isolates of
Staphylococcus aureus (S. aureus) [1]. Infection with
MRSA is associated with increased morbidity, require-
ment of longer duration of antibiotic treatment, higher
healthcare costs, prolonged hospitalization, and an in-
creased risk of death [2-4]. This risk is higher in pa-
tients who have been suboptimally treated either with an
ineffective antibiotic or inadequate surgical intervention.
In recent years, there has been an increase in the num-
ber of MRSA isolates with high vancomycin minimum in-
hibitory concentrations (MICs) [5]. Higher vancomycin
MICs have been associated with prolonged bacteremia
and increased mortality [6,7]. Vancomycin, a tricyclic gly-
copeptide, is the standard first-line treatment for patients
with MRSA bacteremia. However, studies have linked
vancomycin treatment failure in MRSA with higher
vancomycin MICs even at MICs below the Clinical and
Laboratory Standards Institute (CLSI) susceptibility break-
points for S. aureus (≤2 ug/ml) [8-11]. Recent consensus
guidelines recommend that clinicians consider using alter-
native agents for MRSA infection when the vancomycin
MIC is greater than 1 ug/ml [12,13], especially if there is
evidence of clinical failure with regards to vancomycin
treatment.
Daptomycin, a lipopeptide antibiotic, is approved by
the US Food and Drug Administration for the treatment
of S. aureus bacteremia and is considered a reasonable
alternative to vancomycin. The efficacy of daptomycin
has been demonstrated in an open-label randomized
clinical trial by Fowler et al. [14]. In a subgroup analysis
this trial showed that the success rate for daptomycin
was marginally greater (although not statistically signifi-
cant) than the standard treatment among patients with
MRSA bacteraemia (44% for daptomycin versus 31.8%
for standard treatment; P = 0.28). Daptomycin, however,
showed a worse outcome than standard treatment in pa-
tients with left-sided endocarditis due to S. aureus. A subse-
quent report evaluating the MRSA isolates from this study
found that all strains in the vancomycin arm had an MIC of
less than or equal to 1 ug/ml [15], hence it is difficult to
state conclusively whether daptomycin is superior to vanco-
mycin in the treatment of MRSA infections. Three recent
cohort studies comparing daptomycin and vancomycin for
bloodstream infections (BSIs) due to MRSA with a high
vancomycin MIC demonstrated that daptomycin was asso-
ciated with a better outcome, both in terms of rates of clin-
ical success and mortality, compared to vancomycin [16-18].
However, being retrospective non-randomized studies, these
results need to be interpreted with caution.
As there have been no head-to-head randomized clin-
ical trials comparing the treatment efficacy of vanco-
mycin versus daptomycin in the treatment of BSIs due
to MRSA with high vancomycin MICs, the question of
whether alternative treatment confers a benefit in cases
of MRSA BSI with high vancomycin MIC remains. When
treating such infections, clinicians are often faced with the
decision of whether to continue the patient on a well-
established, fairly cheap standard treatment (vancomycin),
or switch to a more expensive alternative such as dapto-
mycin from the outset.
Despite better infection control measures and aware-
ness, we foresee that MRSA will continue to remain a
problem in both our local healthcare setting and inter-
nationally over the coming years. In particular, we also
expect a continued increase in the number of MRSA iso-
lates with high vancomycin MICs. It is thus important
that daptomycin is tested against vancomycin in a rigor-
ous head-to-head randomized clinical trial to ascertain if
either medication represents a more efficacious treat-
ment strategy.
Aims
The aim of our study is to compare the efficacy of dap-
tomycin treatment versus vancomycin treatment in the
treatment of MRSA BSIs due to isolates with high vanco-
mycin MICs. If results from this pilot study suggest that
daptomycin shows significant efficacy, we aim to proceed
with a larger scale confirmatory study. This would help
guide clinicians and inform practice guidelines on the op-
timal treatment for such infections.
Hypothesis
The hypothesis of our trial is that daptomycin treatment
is superior to vancomycin treatment in reducing the 60-
day all-cause mortality rate from BSIs due to MRSA
with high vancomycin MICs from 25 to 10%.
Objectives
The primary objective is to compare the rate of all-cause
mortality at 60 days post index blood culture between par-
ticipants randomized to daptomycin versus those random-
ized to vancomycin for the treatment of MRSA BSIs due
to isolates with high vancomycin MICs (≥1.5 ug/ml).
Index blood culture is defined as the first blood culture
which grows MRSA that has an MIC of more than or
equal to 1.5 ug/ml. The key secondary objective is to com-
pare the rates of ‘clinical failure’ between treatment arms.
Other secondary objectives include comparing time to
microbiological clearance, rates of nephro- and musculo-
skeletal toxicities, and the need to discontinue the study
drug or add an additional anti-MRSA agent due to wors-
ening infection between treatment arms.
Kalimuddin et al. Trials 2014, 15:233 Page 2 of 10
http://www.trialsjournal.com/content/15/1/233
Methods/Design
Study participants
In this pilot study, a minimum of 50 participants will be
recruited over the course of two years, across three aca-
demic teaching hospitals in Singapore (Singapore General
Hospital (SGH), National University Hospital (NUH), and
Tan Tock Seng Hospital (TTSH)). Each hospital’s micro-
biologist will identify patients whose blood cultures are
positive for MRSA with vancomycin MICs of more than
or equal to 1.5 ug/ml using the Epsilometer test (E-test)
method or the VITEK™-2 system (bioMerieux, Marcy
l’Etoile, France) and inform the site trial coordinator.
The site trial coordinator will highlight all such pa-
tients to the investigators. The primary physician will
be approached by one of the investigators for verbal
consent to speak to the patient about possible partici-
pation in the study. After obtaining informed consent
from the patient for participation in the study, the pa-
tient will then be assessed to ensure he/she meets all
the inclusion and exclusion criteria. The patient will
then be randomized to either study treatment. The in-
fectious disease physician will co-manage the patient
together with the primary physician to ensure that all
elements in the protocol are complied with.
During the informed consent process participants will
be asked for consent regarding the archiving of residual
blood specimens for future use in further elucidating
pharmacokinetic and pharmacodynamic parameters as
well as resistance mechanisms of MRSA. This trial has
been granted ethics approval by the Singhealth Centralised
Institute Review Board (CIRB) (approval ID: 2013/846/E).
All information obtained during the course of this study
will be kept strictly confidential and will be kept by study
site. Only the investigators and study staff are able to ac-
cess the information during and after the study. The infor-
mation may also be given to the health authorities, ethics
committees, or other persons required by law. Identifiable
information will never be used in a publication or presen-
tation. In the event of any publication regarding this study,
patients’ identity will remain confidential.
Inclusion criteria
To be eligible for enrolment, patients must be inpatients
above the age of 21 years, have MRSA bacteremia due to
MRSA isolates with a vancomycin MIC ≥ 1.5 ug/ml and
be prepared to undergo all study treatments and proce-
dures and attend follow-ups as per the study protocol.
Exclusion criteria
Subjects meeting any of the following criteria will be ex-
cluded from study participation: 1) Allergy to any of the
study medications, 2) Pregnant or breastfeeding females,
3) Unable to provide consent or have no legally acceptable
representatives, 4) Currently enrolled or within the past
three months participated in an interventional antibiotic
or vaccine trial, 5) >48 hours after MRSA vancomycin
MIC ≥1.5 ug/ml confirmation by the microbiology labora-
tory (assessed from time of lab report), 6) On palliative
care or with less than 24 hours of life expectancy (as dis-
cussed with their primary physicians), 7) Polymicrobial
bacteremia, 8) Pneumonia, 9) On treatment with linezolid,
tigecycline, or ceftaroline immediately prior to enrolment,
10) Previous blood cultures positive for MRSA within the
preceding month, 11) On vancomycin or daptomycin
treatment for more than 96 hours prior to enrolment,
12) On vancomycin or daptomycin treatment for more
than 96 hours prior to enrolment, 13) Baseline serum
creatine kinase (CK) more than 1.5 times the upper
limit of normal, 14) Patients with prosthetic heart valves
or 15) Any other significant condition that would, in the
opinion of the investigator, compromise the patient’s
safety or outcome in the trial.
a. Isolation of a significant organism other than MRSA
from index blood cultures or blood cultures taken
up to two weeks prior to enrolment and/or for
which the patient is still on treatment.
b. Chest x-ray at baseline consistent with pneumonia
AND at least two of the following signs and symptoms:
New onset or worsening cough, purulent sputum or
increased suctioning requirements, dyspnea/tachypnea
or respiratory rate > 30/min, hypoxemia or worsening
gas exchange as determined by the study investigator.
Withdrawal criteria
A patient will be withdrawn from the study if the patient
or legally acceptable representative withdraws consent at
any time or if the investigator deems it is in the best
interest of the patient due to safety concerns.
Any participant withdrawn from the study interven-
tion will remain in follow-up for observation of safety
and efficacy end-points. However, all patients are free to
withdraw completely from the study at any time without
giving a reason. If patients withdraw completely from
study participation no further information will be col-
lected for study purposes.
Study design
This study is a multicenter prospective open-label phase
IIB pilot randomized controlled trial. Participants meet-
ing the inclusion and exclusion criteria will be randomized
to one of two arms: daptomycin treatment (intervention
arm) or vancomycin treatment (active control arm), as
shown in Figure 1. We foresee that a large majority of the
participants would have already been started on vanco-
mycin by their primary physicians at the time of their en-
rolment into the trial. Enrolled participants will thus
be randomized to either continuing on vancomycin or
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switching treatment to daptomycin. The remaining par-
ticipants who have either not been started on any antibi-
otics or are on antibiotics other than vancomycin will be
randomized similarly to either treatment with vancomycin
or daptomycin.
Daptomycin will be dosed intravenously at 6 to 8 mg/kg
once daily. In patients with a creatinine clearance of less than
30 ml/min or on intermittent or continuous hemodialysis
daptomycin will be dosed at 6 to 8 mg/kg every 48 hours.
Daptomycin will be administered after hemodialysis in pa-
tients undergoing intermittent hemodialysis. As per dapto-
mycin approved label recommendations, statins or any other
drugs associated with rhabdomyolysis will be discontinued
in patients who are randomized to the daptomycin treat-
ment arm. As there are currently no recommended guide-
lines for optimal daptomycin trough and peak levels, serum
daptomycin peak (taken within 30 minutes of completion of
daptomycin infusion) and trough levels (taken immediately
before the next dosing of daptomycin) will be systematically
collected on day seven (+/−three days). Aliquot samples will
be archived for future pharmacokinetic and/or dynamic ana-
lysis when new data becomes available. Daptomycin trough
and peak levels will only be drawn and archived in patients
who consent to this.
The duration of treatment will be determined based
on the type of bacteremia. Participants with uncompli-
cated bacteremia will receive a minimum of 14 days anti-
biotics and those with complicated bacteremia or infective
endocarditis will receive a minimum of 28 to 42 days
antibiotics from the date that microbiological clearance is
achieved. Microbiological clearance is defined as two con-
secutive MRSA negative blood cultures. Uncomplicated
bacteremia is defined as the isolation of MRSA from enrol-
ment blood cultures in patients without endocarditis and
without evidence of spread to other organs. Complicated
bacteremia without endocarditis is defined as the persist-
ence of MRSA in blood cultures beyond four days from ini-
tial positive culture, the presence of spread of infection, or
infection of a vascular catheter, implantable cardiac device,
or orthopedic/joint prosthetic implant not removed
within four days. Right-sided endocarditis (complicated
bacteremia) is defined as definite or possible endocarditis
involving the tricuspid or pulmonary valve in patients
without predisposing abnormalities or active infection of
the mitral or aortic valves. Left-sided endocarditis (com-
plicated bacteremia) is defined as definite or possible
endocarditis involving the mitral or aortic valve. In
order to make the above diagnoses, participants will be
required to undergo an echocardiogram within the first
10 days of randomization. The definition of ‘definite’
or ‘possible’ endocarditis will be determined using the
modified Duke criteria [19]. The diagnosis of the type
of bacteremia may change during the course of study
and treatment duration will be changed accordingly.
This decision will be made by the managing physician.
Baseline as well as serial clinical and laboratory data
will be collected as per the trial schedule (Table 1). Par-
ticipants will be monitored daily by their clinical team in
Figure 1 Study schematic. Vancomycin will be dosed intravenously at 15 mg/kg Q12h with appropriate dose adjustments by a pharmacist in
patients with a creatinine clearance of less than 50 ml/min. Trough levels will be monitored pre-third or fourth dose (inclusive of doses received
prior to study enrolment) and doses will be adjusted accordingly by a pharmacist to achieve a trough level of 15 to 20 ug/ml. Subsequently,
vancomycin trough levels will be monitored at least every seven days (+/−three days) but additional levels may be required for dose titration at
the discretion of the pharmacist or the managing physician.
Kalimuddin et al. Trials 2014, 15:233 Page 4 of 10
http://www.trialsjournal.com/content/15/1/233
Table 1 Study trial schedule
Assessments Pre-screening
activity
Screening2 and
Randomization
While on treatment3 Follow-up
period
Day of study Pre-3rd or
4th dose of
vancomycin
1-
61
7
(+/−3)
8-
131
14
(+/−3)
15-
201
21
(+/−3)
22-
271
28
(+/−3)
29-
341
35
(+/−3)
36-
411
42
(+/−3)
43-
481
49
(+/−3)
50-
551
56
(+/−3)
60 days after
index culture15
(−7 or + 14 days)
Informed consent x
Review of eligibility criteria x
Randomization and
dosing4
x
Demographics x
Medical history5 x
Physical examination6 x x x x x x x x x x
Adverse event monitoring7 x x x x x x x x x x x x x x x x x
Concomitant medication
monitoring8
x x x x x x x x x x x x x x x x x x
Adherence check x x x x x x x x x x x x x x x x
Vancomycin MIC9 testing x
FBC10 x x x x x x x x x
Creatinine11 x x x x x x x x x
CK12 x x x x x x x x x
Vancomycin trough level13 x x x x x x x x x
Daptomycin trough and
peak level14
x
Blood culture x15 To be done daily until two consecutive negative sets x
CXR16 x
Echocardiogram17 x
Urine pregnancy test18 x
Charlson comorbidity
index
x
1These assessments to be done only for patients who remain inpatients. 2Screening blood tests: full blood count, creatinine, creatine kinase, as well as chest radiograph will be accepted if done within 48 hours prior
to screening. 3Duration of therapy will be determined based on type of bacteremia. 4Randomization and first dose of study drug may take place up to one day from screening. Eligibility criteria will be reviewed again
if randomization and first dose of study drug takes place one day from screening. 5Full medical history including comorbidities, current medication, allergies, and presenting and current symptoms. 6Includes vital signs
for temperature, blood pressure (systolic and diastolic), heart rate, respiratory rate, and pulse oximetry. Vital sign readings will be considered to be the readings documented by the investigator during the study visit.
7Adverse event monitoring will be done weekly in patients who are receiving treatment in an outpatient setting. 8Concomitant medication monitoring will be done weekly in patients who are receiving treatment in
an outpatient setting. 9Mean inhibitory concentration (MIC) test results done within 48 hours prior to screening can be used. 10Full blood count: hemoglobin, total and differential white blood cell counts, and platelet
count 11Patients with prior end-stage renal failure already on longterm hemodialysis or peritoneal dialysis will not require serum creatinine monitoring. 12Creatine kinase. 13For patients randomized to the vancomycin
arm only. Blood for the first trough level will be drawn immediately prior to infusion of the 3rd or 4th dose of vancomycin (inclusive of doses received prior to study enrolment) and the dose will be adjusted accord-
ingly to achieve a trough level of 15 to 20 ug/ml. For patients whose 3rd or 4th dose of vancomycin was received prior to study enrolment, a vancomycin trough level should be taken within 48 hours of enrolment. All
patients will have a trough level measured at least every seven days (+/−three days) but additional levels may be required for dose titration at the discretion of the pharmacist or the managing physician. 14For patients ran-
domized to the daptomycin arm only. Blood for the trough level will be drawn immediately prior to the infusion of daptomycin and blood for the peak level will be drawn 30 minutes after the infusion
has completed. This will only be done once on day seven (+/−three days) of the study. 15The index blood culture is the first blood culture which grows MRSA that has an MIC ≥ 1.5 ug/ml obtained in the
pre-screening period. 16Chest radiograph.17Echocardiogram will be done once within the first 10 days of randomization.18Only for female patients of child-bearing potential.
MIC =minimum inhibitory concentration, FBC= full blood count, CK = creatine kinase, CXR= chest radiograph.
Kalim
uddin
et
al.Trials
2014,15:233
Page
5
of
10
http://w
w
w
.trialsjournal.com
/content/15/1/233
the hospital until discharge, with weekly assessments (with
a window period of +/−three days) by the study team dur-
ing the course of the study. All participants will be asked
to return for a follow up assessment 60 days after the
index culture (with a window period of -7 or +14 days).
All participants will be initiated on antibiotic treat-
ment as inpatients, however, participants in either arm
may receive their antibiotics at the outpatient antibiotic
therapy (OPAT) clinic of the individual hospitals. Partici-
pants with end-stage renal failure on hemodialysis may
receive their antibiotics at their respective hemodialysis
centre. Participants will need to achieve microbiological
clearance and be deemed clinically stable by their man-
aging physicians before they can be allowed to receive
their antibiotics at the OPAT clinic or the hemodialysis
centre as per standard clinical practice. However, all
such participants will be required to return to the site
weekly for adherence checks, adverse event monitoring,
and blood tests as per the trial schedule (Table 1).
Randomization
Balanced treatment assignments at a 1:1 ratio will be
achieved using permuted block randomization stratified
by site, with the use of a computer-generated list of ran-
dom numbers. Stratification by site is used to ensure
balance between the study treatment arms across sites.
Random permuted blocks are used to ensure balance
over time. The block length is determined by the statisti-
cian preparing the randomization list and will not be
known by the clinical investigators or site personnel.
The randomization list will be generated by the Singapore
Clinical Research Institute (SCRI). Randomization will be
done via direct web randomization system. Authorized
site personnel will randomize the patients via a password-
protected internet website. The web randomization sys-
tem will then determine the study treatment arm and
provide a subject number to be used for the patient.
Sealed opaque backup randomization envelopes will also
be provided to the site in case of any internet failure.
Study visits and procedures
Randomization will occur at the screening visit after the
eligibility criteria have been met and informed consent
has been obtained. The study treatment will be com-
menced immediately post-randomization. The screening
visit will include the following procedures: written in-
formed consent, documentation of demographic data, full
medical history including comorbidities and current medi-
cations, physical examination including measurement of
blood pressure, pulse rate, respiratory rate, temperature
and oxygen saturation, calculation of the Charlson comor-
bidity index [20], baseline blood tests including full blood
count (FBC), creatinine, and serum CK, calculation of cre-
atinine clearance which will be calculated manually using
the modification of diet in renal disease (MDRD) equation
[21], chest x-ray (CXR), and urine pregnancy test (in fe-
males of child-bearing age). Screening blood tests and
CXR will be accepted if they have been performed within
48 hours of screening. A review of the eligibility criteria
will be repeated on the date of randomization and first
dose of the study treatment if randomization and receipt
of the first dose of the study treatment occurs one day
after screening.
The following tests and assessments will be done dur-
ing the course of the study: blood cultures will be per-
formed daily until two consecutive negative sets are
achieved; blood tests for FBC, creatinine and serum CK
every seven days (+/−three days); vancomycin trough
level pre- third or fourth dose of vancomycin for pa-
tients in the vancomycin arm (inclusive of doses re-
ceived prior to enrolment) and then every seven days
(+/−three days); weekly clinical assessment including a
physical assessment; and an echocardiogram done at
least once within the first 10 days of randomization.
At day seven (+/−three days) daptomycin trough and
peak levels will be taken for participants in the dapto-
mycin arm who consent to the archiving of their blood
specimens.
Participants will return 60 days (−7 or + 14 days) from
time of index blood culture to determine mortality sta-
tus and to obtain a blood culture. During this visit, par-
ticipants will also be asked if they have had to be readmitted
to hospital or have sought medical attention since discharge.
The details of readmission will be sought by reviewing the
participant’s medical records. In particular, we will find out if
participants have had any positive blood cultures for MRSA
during this period. Patients who do not achieve microbio-
logical clearance by 60-days post index culture will be cen-
sored and will still receive treatment outside of the trial
period.
If a participant does not return for the final study visit (60
days from the time of index blood culture) attempts will be
made to contact the participant for up to 14 days from the
date of the final study visit. If the patient has not responded
by this time they will be considered lost to follow-up. Table 1
summarizes the study visits and procedures.
Study endpoints
The primary endpoint is all-cause mortality 60 days
from the date of positive index blood culture. The index
culture is defined as the first blood culture which grows
MRSA that has an MIC of more than or equal to 1.5 ug/ml.
The date of index blood culture is the date that the patient’s
blood was drawn for this blood culture.
The secondary efficacy endpoints of the study are as
follows: 1) Clinical failure defined as composite of all-
cause mortality 60 days from the index blood culture,
microbiologic failure (defined as growth of MRSA in
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blood cultures more than or equal to seven days from
index blood culture while the patient is still on treat-
ment) and/or a recurrence (defined as a positive blood
culture for MRSA at any point in time from the point of
microbiological clearance up to 60 days from the index
blood culture) of MRSA BSI, 2) Clinical failure defined
as a composite of microbiologic failure and/or a recur-
rence of MRSA BSI, 3) Clinical failure defined a composite
of all-cause mortality 60 days from the index blood culture
and/or microbiologic failure and 4) Time to microbio-
logical clearance is defined as the time from index blood
culture to the first MRSA negative blood culture which is
followed by a second MRSA negative blood culture
The safety endpoints include: 1) Nephrotoxicity de-
fined as an increase in the serum creatinine level of
50 umol/L from baseline or 50% above baseline through-
out the course of the study, in the absence of an alterna-
tive explanation, 2) Musculoskeletal toxicity defined by a
rise in CK of five times the upper limit of normal from
baseline during the course of the study, 3) The need to
stop the study drug due to toxicity as defined by the Com-
mon Terminology Criteria for Adverse Events version
4.03 (CTCAE) [22], 4) The need to discontinue study
treatment due to worsening infection while on study
treatment.
Other exploratory endpoints include all-cause mortal-
ity 60 days from the time of the index blood culture and
clinical failure of daptomycin treatment versus vanco-
mycin treatment in the four subtypes of bacteremia (as
per the patient’s final diagnosis), that is, uncomplicated
bacteremia, complicated bacteremia without endocardi-
tis, right-sided endocarditis, and left-sided endocarditis.
Study intervention
Vancomycin and daptomycin are approved post-marketed
drugs, which are routinely used in clinical practice. Each
site will use the local stocks of the study drugs available at
the institution at the time of dispensing. The study drugs
will be stored, ordered, and dispensed as per each institu-
tion’s practice and applicable policies.
The active control arm will be vancomycin adminis-
tered intravenously. Vancomycin will be dosed at 15 mg/
kg every 12 hours with appropriate dose adjustments by
a pharmacist in patients with a creatinine clearance less
than 50 ml/min, so as to achieve a vancomycin trough
level of 15 to 20 ug/ml. This dosing regimen is based on
a consensus statement of the American Society of Health-
System Pharmacists, the IDSA, and The Society of Infec-
tious Diseases Pharmacists on guidelines for vancomycin
dosing [12,23].
The intervention arm will be daptomycin administered
intravenously. IDSA guidelines recommend a dose of 6
mg/kg every 24 hours but suggest a higher dose of 10 mg/
kg every 24 hours for patients with vancomycin treatment
failure and/or persistent bacteremia [13]. Some experts,
however, do recommend a higher dose of at least 8 mg/kg
in all cases in view of the concentration-dependent effect
of the drug [24-26]. The main concern with high dose
daptomycin is an increased risk of musculoskeletal
toxicity, however studies have not demonstrated this.
In a retrospective review of 61 patients by Fiqueroa
et al. [24], patients received a mean dose of 8 mg/kg of
daptomycin (range 7 to 11 mg/kg) for a median of 25 days.
This dose of drug was well tolerated and the incidence of
significant CK elevation was 4.9% which resolved after dis-
continuation of the drug. This rate is comparable to other
studies in which a lower dose of daptomycin was used [14].
In a retrospective multicenter review of 250 adults who re-
ceived daptomycin at doses more than or equal to 8 mg/kg
for complicated gram-positive infections [26], only three
patients (1.2%) developed an adverse event attributable to
high dose daptomycin, with the event either considered
mild or moderate. The median end-of-therapy CK level
was within the normal range. Doses of up to 12 mg/kg have
also been shown to be well tolerated in healthy volunteers
[25]. In this study, daptomycin will be dosed intravenously
at 6 to 8 mg/kg every 24 hours.
Patients with uncomplicated bacteremia will receive a dose
of 6 mg/kg every 24 hours. Patients with suspected compli-
cated bacteremia or endocarditis, or in receipt of at least two
doses of vancomycin in the last 90 days (apart from vanco-
mycin received for their current MRSA bacteremia) will
receive a dose of 8 mg/kg every 24 hours.
If during the course of the study patients who were
initially thought to have an uncomplicated bacteremia
subsequently develop a complicated bacteremia or endo-
carditis, the dose of daptomycin will be increased from 6
to 8 mg/kg. The reverse applies to those who were ini-
tially suspected to have a complicated bacteremia or
endocarditis but who subsequently were found to only
have an uncomplicated bacteremia (the dose will be de-
creased from 8 to 6 mg/kg).
In patients with a creatinine clearance of less than 30
ml/min or on intermittent or continuous hemodialysis
daptomycin will be dosed at 6 to 8 mg/kg every 48
hours. The same criteria as above applies as to whether
they receive 6 or 8 mg/kg every 48 hours. Daptomycin
will be administered after hemodialysis in patients
undergoing intermittent hemodialysis. There are currently
no recommended trough or peak level for daptomycin.
Safety considerations
The site investigator of each study site is responsible for
monitoring the safety of patients for that particular study
site. Immediate medical attention should be provided to
resolve any serious adverse event (SAE), which occurs
during the study. All adverse events (AEs) and SAEs oc-
curring from the time the patient has given written
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informed consent and during the study will be followed
until resolution. AEs will be graded using the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE), version 4.03 [22]. The rela-
tionship of the event to the study drug and whether the
event is an expected or not will be assessed using the
listing of adverse effects contained in the summary of
the product characteristics for the antibiotics used. All
SAEs that are unexpected and related to the study drug
will be reported to the Health Sciences Authority (HSA).
An independent Data Safety and Monitoring Board
(DSMB) comprising two independent physicians and a
biostatistician shall be established prior to commencing
the study. Interim analyses including both key efficacy
and safety endpoints will be performed after the first 25
patients have been assessed 60 days from index blood
culture. Any significant difference in efficacy or safety
will be highlighted to the Trial Steering Committee
(comprising all the site investigators and the principal
investigator), along with the DSMB’s recommendations
for action. If there is a significant safety concern, the
DSMB may recommend to the Trial Steering Committee
that the trial should be stopped.
Data collection and storage
The quality of the data collected will be monitored regu-
larly by the site principal investigator. Monitoring is
done in order to verify that the trial is conducted in
compliance with the Singapore Guideline for Good Clin-
ical Practice.
All study staff will be trained in the execution of study
procedures including data collection, and entry and train-
ing will be recorded in the study site file. The site coordin-
ator will record data from the source documents into a
central electronic database. The system will allow for audit
tracking. Essential documents will be retained for a mini-
mum of six years after completion or discontinuation of
the study.
Determination of sample size
In this pilot study we aim to evaluate the efficacy of the
daptomycin versus vancomycin at 60-days post index
blood culture for a decision to proceed with a larger
scale confirmatory study. For this purpose, Simon’s ran-
domized selection design is used [27], and a total of 21
participants per arm are needed so as to guarantee a
90% probability of correctly selecting the daptomycin
arm as superior to the vancomycin arm if it is truly su-
perior by a margin of 15%. This is assuming a survival
rate of 75% at 60-days post index blood culture in the
vancomycin arm compared to the survival rate of 90% in
the daptomycin arm, based on previously published
retrospective case–control and cohort studies [16-18].
This type of design is to select one of two arms as being
worthy of further evaluation in a subsequent study but
not to confirm the superiority of the selected arm. As-
suming an attrition rate of 20%, target recruitment is a
minimum 50 patients over the course of two years.
Statistical analysis
All statistical analyses will be carried out on an intention-
to-treat (ITT) basis unless otherwise stated. Continuous
variables will be summarized using mean and standard de-
viation. Categorical variables will be summarized using
the number of observations and percentages. All tests of
hypotheses will be two-tailed. Statistical significance will
be considered to be P = 0.05 unless otherwise stated. All
statistical analyses will be performed using SAS Version
9.2 (SAS Institute Inc, Cary, North Carolina, USA) or
higher Statistical analysis and programming support will
be provided by SCRI.
An ITT population is defined as all randomized pa-
tients. The treatment group of patients in the ITT popu-
lation is the planned treatment group, that is, according
to the randomization list planned prior to the study
commencement. A per protocol (PP) population is de-
fined as all randomized patients who have taken at least
one dose of study treatment and have had the primary
endpoint measured. The treatment group of patients in
the PP population is according to the treatment actually
received after the randomization. Patients will be assigned
to the group as per the first dose received of the study
treatment after the randomization. If patients are issued
the incorrect study treatment they should continue on this
treatment and not switch. For example if a patient was
randomized to vancomycin but the first treatment they re-
ceived after randomization was daptomycin they should
continue to take daptomycin. The treated population is
the same as the PP population but without the require-
ment that the primary endpoint is measured. The treated
population is defined as all randomized patients who
have taken at least one dose of study treatment after
randomization. The treatment group of patients in the
treated population is according to the first treatment
actually received after the randomization.
Demographic characteristics (age, gender, and so forth)
and other baseline characteristics (such as clinical mea-
sures taken at baseline) will be summarized using descrip-
tive statistics by treatment group for the ITT population.
The primary analysis will be conducted on the ITT popu-
lation. The Fisher’s exact test will be used to compare
60-day mortality from the index blood culture (primary
endpoint) between the two treatment groups and the
exact 95% confidence interval will be calculated using the
Clopper and Pearson method. Primary analysis will be
conducted using a two-sided alpha of 0.05. For the pri-
mary analysis, dropouts will be imputed as mortality. A
sensitivity analysis will be performed similar to the
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primary analysis but using the PP population. Addition-
ally, the time from index blood culture to death for each
treatment group will be calculated using the Kaplan-
Meier product-limit method for the ITT population, cen-
soring at the 60-day post index culture assessment. Those
lost to follow-up or totally withdrawn from study will be
censored at the date of last follow-up. A sensitivity ana-
lysis will be performed by fitting a Cox regression model
to estimate the hazard ratio and its associated 95% confi-
dence interval. The Fisher’s exact test will also be used to
compare clinical failure (according to the three definitions
as described in the section ‘Study endpoints’) between the
treatment arms for the ITT population and the exact 95%
confidence interval will be calculated using the Clopper
and Pearson method.
For the ITT population, dropouts will be imputed as
‘clinical failure’ if the patient meets the following criteria
under the respective definition of the clinical failure
endpoint:
Definition 1 (Moore et al. [16]): 1) contact could not
be established or patient reported dead at the 60-day
post index culture assessment; or 2) growth of MRSA in
at least one blood culture seven days after index culture
whilst patient is still on treatment, or if no cultures are
performed after seven days of index culture and last cul-
ture (within seven days of index culture whilst still on
treatment) was positive for MRSA; or 3) any positive
blood culture after microbiological clearance, or in the
absence of a blood culture after microbiological clear-
ance, contact made and patient reporting any readmis-
sion to hospital.
Definition 2 (Cheng et al. [17]): 1) growth of MRSA in
at least one blood culture seven days after index culture,
or if no cultures performed after seven days of index cul-
ture and last culture (within seven days of index culture
whilst still on treatment) was positive for MRSA; or 2)
any positive blood culture after microbiological clear-
ance, or in the absence of a blood culture after micro-
biological clearance, contact made and patient reporting
any readmission to hospital.
Definition 3 (Murray et al. [18]): 1) contact could
not be established or patient reported dead at the 60-
day post index culture assessment; or 2) growth of
MRSA in at least one blood culture seven days after
index culture or if no cultures performed after seven
days of index culture and last culture (within seven
days of index culture whilst still on treatment) was
positive for MRSA.
The Cox regression model will be used to compare
time to microbiological clearance between the treatment
groups for ITT population, censoring at the 60-day post
index culture assessment. Those lost to follow-up or to-
tally withdrawn from study will be censored at the date
of last follow-up.
The analysis of safety endpoints will be performed on
the treated population. The reporting period for safety
data will be from the date of the first dose of study treat-
ment to 30 days after the last dose is received. Numbers
and percentages of patients calculated will be based on: 1)
experiencing nephrotoxicity and musculoskeletal toxicity,
2) needing to stop the study drug due to toxicity, 3) need-
ing to discontinue study treatment due to worsening in-
fection, or 4) needing to have an additional anti-MRSA
agent added to their treatment due to worsening infection
between randomization and end of study (treatment will
be reported by the study treatment arm). The frequency
of AEs with severity and relation with the study treatment
will be reported by the treatment arm. All SAEs will be
listed by the study treatment arm and details of the events
will be summarized.
Discussion
As far as we are aware, this is the first head-to-head ran-
domized trial comparing the safety and efficacy of dapto-
mycin and vancomycin in the treatment of MRSA BSIs
with high vancomycin MICs. If results from this pilot
study suggest that daptomycin shows significant efficacy
in the treatment of such infections, we aim to proceed
with a larger scale confirmatory study. This would help
guide clinicians and inform practice guidelines on the
optimal treatment for such infections.
Trial status
The trial has been granted a clinical trials certificate
(CTC) by the Health Sciences Authority (HSA) (Certifi-
cate number: CTC1300508). Recruitment will start in
February 2014.
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